$14.47
1.19%
Nasdaq, Fri, Nov 01 2024
ISIN
US14888D2080
Symbol
CBIO
Sector
Industry

Catalyst Biosciences, Inc. Stock price

$14.47
+2.20 17.93% 1M
+0.61 4.40% 6M
-11.22 43.67% YTD
+8.18 130.05% 1Y
+10.44 259.25% 3Y
+7.57 109.83% 5Y
-606.63 97.67% 10Y
Nasdaq, Closing price Fri, Nov 01 2024
+0.17 1.19%
ISIN
US14888D2080
Symbol
CBIO
Sector
Industry

Key metrics

Market capitalization $1.35b
Enterprise Value $1.36b
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 20.51
Dividend yield 0.00%
Last dividend (FY23) $1.80
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.75m
Free Cash Flow (TTM) Free Cash Flow $-10.80m
Cash position $25.10m
EPS (TTM) EPS $-17.57
P/E forward 31.73
P/S forward 9.52
EV/Sales forward 9.59
Short interest 0.11%
Show more

Is Catalyst Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Catalyst Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Catalyst Biosciences, Inc. forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Catalyst Biosciences, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Catalyst Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
100% 100%
-
- -
-
-
- Selling and Administrative Expenses 13 13
24% 24%
-
- Research and Development Expense 1.97 1.97
92% 92%
-
-15 -15
64% 64%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
65% 65%
-
Net Profit -44 -44
472% 472%
-

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Han Ying
Employees 4
Founded 1997
Website www.gyretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today